Related Experiment Video

Updated: Jun 14, 2026

Primary Orthotopic Glioma Xenografts Recapitulate Infiltrative Growth and Isocitrate Dehydrogenase I Mutation
09:43

Primary Orthotopic Glioma Xenografts Recapitulate Infiltrative Growth and Isocitrate Dehydrogenase I Mutation

Published on: January 14, 2014

8.4K

Author Correction: Cross-species comparison reveals therapeutic vulnerabilities halting glioblastoma progression

Leo Carl Foerster1,2, Oguzhan Kaya1,2, Valentin Wüst2,3

  • 1Molecular Neurobiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.

Nature Communications
|October 17, 2025
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Bioluminescence Imaging of an Immunocompetent Animal Model for Glioblastoma
09:17

Bioluminescence Imaging of an Immunocompetent Animal Model for Glioblastoma

Published on: January 15, 2016

15.4K
A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells
05:29

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells

Published on: March 28, 2021

3.2K

Related Experiment Videos

Last Updated: Jun 14, 2026

Primary Orthotopic Glioma Xenografts Recapitulate Infiltrative Growth and Isocitrate Dehydrogenase I Mutation
09:43

Primary Orthotopic Glioma Xenografts Recapitulate Infiltrative Growth and Isocitrate Dehydrogenase I Mutation

Published on: January 14, 2014

8.4K
Bioluminescence Imaging of an Immunocompetent Animal Model for Glioblastoma
09:17

Bioluminescence Imaging of an Immunocompetent Animal Model for Glioblastoma

Published on: January 15, 2016

15.4K
A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells
05:29

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells

Published on: March 28, 2021

3.2K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Articles linked to this work by shared authors, journal, and citation graph.

Tailless terminates the neural stem cell temporal cascade in both the optic lobe and central brain.

Development (Cambridge, England)·2026

Haemodynamic control of zonated liver function via instructive vascular Wnt signalling.

Nature communications·2026

Revealing the Influence of Hole Transport Layer on the Stability of Blue Quantum Dot Light-Emitting Diodes.

The journal of physical chemistry letters·2026

Diagnostic approaches and clinical challenges of imaging in peripheral nerve tumors: data from the multicenter Peripheral Nerve Tumor Registry.

Journal of neurosurgery·2026

Epistemology of Kocher's Point.

Neurosurgery·2026

Impact of ABO Blood Group on Vascular Complications and on Clinical and Functional Outcome After Aneurysmal Subarachnoid Hemorrhage.

Neurology international·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us